LncRNAs act as prognostic biomarkers in bladder carcinoma: A meta-analysis

BACKGROUND AND PURPOSE: Increasing studies have shown that different kinds of lncRNAs play key role in the development of multiple carcinomas. Therefore, we conducted a meta-analysis to investigate an association between the expression level of lncRNAs and the prognosis of bladder cancer (death or other clinical outcomes). METHODS: A systematic literature search was performed by using PubMed. Twenty-four studies were included in the meta-analysis based on the inclusion and exclusion criteria. In total, there are 1652 independent participants. RESULTS: The result showed that high expression levels of lncRNAs were demonstrated to be associated with poor overall survival (OS) (HR = 2.33, 95%CI: 1.51–2.39, p < 0.01) in bladder carcinoma, but there was no significant correlation between lncRNAs level and recurrence-free survival (RFS) (pooled HR = 1.57, 95%CI 0.69–3.56, p = 0.284), and progression-free survival (PFS) (pooled HR = 1.37, 95%CI 0.79–2.38, p = 0.269). Additionally, increased lncRNAs expression was found to be moderately correlated with tumor stage and progression (II/III/IV vs. I, OR = 3.20, 95%CI: 1.72–5.98, p < 0.001). In addition, elevated lncRNAs expression predicted lymph node metastasis (LNM) significantly (pooled OR = 2.29, 95 % CI 1.33–3.95, p < 0.01). No significant heterogeneity was observed among studies except lymph node metastasis. CONCLUSION: In conclusion, high expression levels of lncRNAs were demonstrated to be associated with poor OS and positive LNM, and lncRNAs might be potential prognostic markers in bladder cancer.